Barinthus Biotherapeutics plc (BRNS) - Total Liabilities
Based on the latest financial reports, Barinthus Biotherapeutics plc (BRNS) has total liabilities worth $24.64 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Barinthus Biotherapeutics plc - Total Liabilities Trend (2019–2024)
This chart illustrates how Barinthus Biotherapeutics plc's total liabilities have evolved over time, based on quarterly financial data. See BRNS working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Barinthus Biotherapeutics plc Competitors by Total Liabilities
The table below lists competitors of Barinthus Biotherapeutics plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mustang Industrial
TWO:5460
|
Taiwan | NT$84.79 Million |
|
Wijaya Karya Bangunan Gedung Tbk PT
JK:WEGE
|
Indonesia | Rp2.31 Trillion |
|
Atlas Pearls Ltd
AU:ATP
|
Australia | AU$11.40 Million |
|
BPL Limited
NSE:BPL
|
India | Rs3.28 Billion |
|
Asian Hotels (East) Limited
NSE:AHLEAST
|
India | Rs4.72 Billion |
|
West High Yield Resources Ltd
V:WHY
|
Canada | CA$8.89 Million |
|
Wulff-Yhtiot Oy
HE:WUF1V
|
Finland | €38.10 Million |
|
Greenyield Bhd
KLSE:0136
|
Malaysia | RM66.56 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Barinthus Biotherapeutics plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BRNS market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Barinthus Biotherapeutics plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Barinthus Biotherapeutics plc (2019–2024)
The table below shows the annual total liabilities of Barinthus Biotherapeutics plc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $30.19 Million | +9.75% |
| 2023-12-31 | $27.51 Million | +1.88% |
| 2022-12-31 | $27.00 Million | -4.08% |
| 2021-12-31 | $28.15 Million | -47.68% |
| 2020-12-31 | $53.81 Million | +30.86% |
| 2019-12-31 | $41.12 Million | -- |
About Barinthus Biotherapeutics plc
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targetin… Read more